Results 171 to 180 of about 202,276 (321)

Review on enhancing clinical decision support system using machine learning

open access: yesCAAI Transactions on Intelligence Technology, EarlyView.
Abstract Clinical decision‐making is a complex patient‐centred process. For an informed clinical decision, the input data is very thorough ranging from detailed family history, environmental history, social history, health‐risk assessments, and prior relevant medical cases.
Anum Masood   +4 more
wiley   +1 more source

Identification of intratumoral microbiome-driven immune modulation and therapeutic implications in diffuse large B-cell lymphoma [PDF]

open access: gold
Zheng Yijia   +13 more
openalex   +1 more source

Two cases of primary diffuse large B-cell lymphoma of the CNS associated with t(8;14)(q24;q32) or t(3;14)(q27;q32) identified by G-banding and fluorescence <i>in situ</i> hybridization applied to metaphase spreads

open access: gold, 2022
Hitoshi Ohno   +11 more
openalex   +2 more sources

Laparoscopic Splenectomy for Inflammatory Pseudotumor‐Like Follicular Dendritic Cell Sarcoma: A RareEpstein–Barr Virus‐Associated Splenic Tumor

open access: yes
The Kaohsiung Journal of Medical Sciences, EarlyView.
Hsin‐Yi Lin   +3 more
wiley   +1 more source

Immunoprofiling Reveals GATA3 as a Prognostic Marker in Transformed Mycosis Fungoides

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Transformed mycosis fungoides (TMF) is a rare, aggressive variant of cutaneous T‐cell lymphoma characterized by the presence of large neoplastic cells and poor clinical outcomes. A retrospective cohort of 22 TMF patients was analyzed using immunohistochemistry on formalin‐fixed, paraffin‐embedded (FFPE) tissue for GATA3 (n = 20), T‐bet (n = 22)
Bruno de Castro e Souza   +5 more
wiley   +1 more source

Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma.

open access: green, 2015
Bo Jia   +18 more
openalex   +2 more sources

Meta‐Analysis: High anti‐HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
This meta‐analysis demonstrates a significantly lower risk for HBV reactivation on rituximab if anti‐HBs is > 100 iU/L (3.5%, CI: 1.8%–6.9%) vs. anti‐HBs between 10 and 100 iU/L (13.8%, CI: 8.8%–20.8%) and anti‐HBs negative (27.3%, CI: 20.0%–36.0%). Thus, if anti‐HBs titer is > 10 iU/L, monitoring could be considered.
Shiva Poola   +4 more
wiley   +1 more source

Primary Diffuse large B-cell lymphoma of spleen: A rare case report

open access: yesMediterranean Journal of Hematology and Infectious Diseases, 2014
Primary splenic lymphoma is very rare with an incidence less than 1% and, 22% to 33% of the cases being diffuse large B-cell lymphoma with a relatively favourable prognosis.
Biswajit Dey   +5 more
doaj  

Home - About - Disclaimer - Privacy